1. Home
  2. CERS vs HUMA Comparison

CERS vs HUMA Comparison

Compare CERS & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$2.59

Market Cap

276.0M

Sector

Technology

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$1.05

Market Cap

308.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERS
HUMA
Founded
1991
2004
Country
United States
United States
Employees
N/A
184
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.0M
308.6M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CERS
HUMA
Price
$2.59
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$6.19
AVG Volume (30 Days)
2.3M
7.5M
Earning Date
04-30-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
27.27
N/A
EPS
N/A
N/A
Revenue
$51,326,000.00
N/A
Revenue This Year
$19.95
$444.16
Revenue Next Year
$8.84
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
30.68
N/A
52 Week Low
$1.15
$0.55
52 Week High
$3.15
$2.84

Technical Indicators

Market Signals
Indicator
CERS
HUMA
Relative Strength Index (RSI) 50.37 44.76
Support Level $1.94 $0.89
Resistance Level $2.68 $1.28
Average True Range (ATR) 0.16 0.13
MACD -0.05 -0.02
Stochastic Oscillator 20.90 12.13

Price Performance

Historical Comparison
CERS
HUMA

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: